Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
This study has been completed.
Study NCT00004122 Information provided by National Cancer Institute (NCI)
First Received: December 10, 1999 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bladder Cancer
Additional conditions recognized in this trial
Urinary Bladder Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
BCG vaccine
recombinant interferon alfa
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon Alfa-2b
Interferon Type I, Recombinant
Interferon-alpha
Interferons
More general drug interventions related to this trial
Adjuvants, Immunologic
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Back to top of Main Content
